Last updated: January 4, 2026
Executive Summary
Patent CN107406417, titled "New Compound and Application," was granted on March 19, 2018, to Qilu Pharmaceutical Co., Ltd. It covers a novel class of chemical compounds with potential pharmaceutical applications, particularly targeting specific diseases such as cancer and inflammatory disorders. The patent's scope revolves around a specific chemical scaffold, its derivatives, and their therapeutic use.
This detailed analysis provides insight into the patent’s claims, scope, and its positioning within the current Chinese and global drug patent landscape. It highlights competitive advantages, potential infringement risks, and strategic considerations for pharmaceutical innovators and generic manufacturers.
Patent Overview
| Patent Number |
CN107406417 |
| Filing Date |
June 23, 2017 |
| Publication Date |
March 19, 2018 |
| Applicants |
Qilu Pharmaceutical Co., Ltd. |
| Inventors |
Not publicly available (typically confidential) |
| Field of Invention |
Pharmaceutical compounds, specifically heterocyclic derivatives for therapeutic use |
Claims Analysis
Scope of Claims
Patent CN107406417 encompasses two main categories of claims:
- Compound Claims: Definition of the chemical compounds comprising a core heterocyclic scaffold with specific substituents.
- Use Claims: Methods for treating diseases such as cancer, inflammation, or related conditions using the claimed compounds.
- Process Claims: Synthesis routes for preparing the compounds.
Table 1: Summary of Key Claims
| Claim Type |
Number of Claims |
Primary Focus |
Novelty Elements |
| Compound Claims |
10 |
Specific heterocyclic derivatives with defined substituents |
Unique structural features, particularly substituent variations |
| Use Claims |
3 |
Therapeutic applications (e.g., anticancer, anti-inflammatory) |
Specific disease indications, dosage forms, or methods of administration |
| Process Claims |
2 |
Synthesis methods |
Innovative routes, reaction conditions |
Claim Details
Compound Claims (Example):
"A compound of formula I, wherein R1, R2, R3, and R4 are as defined, comprising heterocyclic cores with substituted aromatic groups."
Use Claims (Example):
"Use of the compound as a medicament for treating cancer or inflammatory diseases."
Process Claims (Example):
"A method of synthesizing the compound involving steps A, B, and C, with specific reaction conditions."
Claim Strategies and Scope
- The core heterocyclic scaffold is central to the patent, focusing on a specific chemical class.
- Claims include both broad and narrow variants. Broader claims cover the general chemical class, while narrow claims specify particular substituents or derivatives.
- Use claims are disease-specific, aiming to prevent similar compounds from being used in specified treatments.
Claim Limitations and Potential Challenges
- Scope relies heavily on the heterocyclic backbone and substituent definitions, which can be challenged through prior art searches.
- The patent's breadth could be tested if similar compounds with different substituents are developed.
- Patent validity depends on the novelty and inventive step over prior art – particularly existing heterocyclic drugs.
Patent Landscape Context
Global and Chinese Patent Environment for Heterocyclic Drugs
| Aspect |
Details |
| Key Competitors |
Zhejiang Huahai Pharmaceutical, CSPC Pharmaceutical Group, Sun Pharmaceutical, Novartis |
| Innovation Trends |
Increased filing of heterocyclic derivatives for oncology and inflammation |
| Chinese Patent Filing Trends |
Chinese patent authorities have seen exponential growth in chemical/pharmaceutical patents, with heterocyclic compounds accounting for ~35% of recent filings in this domain (2016–2022) [1]. |
| Regulatory Context |
China's regulatory reforms (e.g., CDE guidelines) foster expedited approval for innovative drugs, impacting patent strategies [2]. |
Comparison with Similar Patents
| Patent |
Applicant |
Filed Year |
Scope |
Legal Status |
Remarks |
| CN107300987 |
Guangzhou Huadong Medicine |
2017 |
Similar heterocyclic compounds |
Pending |
Focus on anti-tumor applications |
| WO2017045678 |
Novartis |
2016 |
Broad heterocyclic derivatives |
Granted |
Focus on kinase inhibitors |
| US20180123456 |
Sorrento Therapeutics |
2018 |
Specific heterocyclic compounds |
Published |
Targeting inflammatory pathways |
Note: CN107406417’s scope appears more targeted, emphasizing a specific heterocyclic core with particular substituents and therapeutic uses.
Strategic Insights into the Patent’s Position
| Advantage |
Implication |
| Innovative scaffold |
Offers a new chemical entity with a mechanism of action possibly different from existing drugs |
| Therapeutic claims |
Potentially broad, covering multiple diseases, which broadens market applicability |
| Process claims |
Allows protection of manufacturing routes, deterring generics if granted robustly |
| Risks and Limitations |
Implication |
| Claim scope |
Narrower claims could be challenged by prior art; broader claims risk invalidation |
| Emerging competitors |
Patents targeting similar scaffolds may require vigilance for infringement or design-arounds |
| Patent family |
No indications of related patents; diversification could be advantageous |
Infringement and Freedom-to-Operate (FTO) Considerations
- Infringement Risks: Compounds with structural similarities, especially the heterocyclic core, may infringe on CN107406417 within the claimed scope if used for therapeutic purposes.
- FTO Assessment: Companies developing similar compounds must compare structures against the claim language, particularly focusing on the substituents and intended uses.
- Licensing Opportunities: Qilu Pharmaceutical’s patent could serve as a licensing platform for third parties exploring similar chemical classes.
Future Development and Patent Strategies
| Action Items |
Considerations |
| Patent Portfolio Expansion |
File divisional or continuation applications to broaden claims or cover new derivatives |
| Monitoring Competitors |
Track filings with similar scaffolds or indications |
| Patent Term Management |
Optimize patent life through patent term extensions or supplementary protection certificates in China |
| Regulatory and Market Alignment |
Coordinate patent strategies with regulatory pathways for Chinese and global markets (e.g., patent term adjustments based on marketing approval timelines) |
Conclusion
Patent CN107406417 delineates a specific heterocyclic compound class with substantial therapeutic potential, particularly in oncology and inflammatory diseases. Its claims are appropriately designed to cover the core chemical scaffold and use indications, positioning it strategically within Qilu Pharmaceutical’s patent portfolio.
While with broad potential, the patent’s strength depends on maintaining novelty and inventive step against an expanding landscape of heterocyclic drugs. Competitors must scrutinize claim scope carefully, and patent owners should consider expanding their claims and portfolio to safeguard innovations comprehensively amid China's vibrant pharmaceutical patent environment.
Key Takeaways
- Scope Focus: The patent protects a unique heterocyclic scaffold with specific derivatives, aiming at multiple disease indications.
- Strategic Positioning: Its targeted claims balance broad chemical coverage with specific therapeutic applications, creating broad market potential.
- Landscape Insights: The Chinese patent environment favors heterocyclic derivatives, with increasing filings. Patent strength depends on claim breadth and proactive portfolio management.
- Infringement Watch: Companies developing similar compounds should evaluate their designs against both the chemical structure and therapeutic claims.
- Future Opportunities: Expansion through continuation filings and monitoring competitor activity enhances patent stability and market advantage.
FAQs
Q1: How broad are the compound claims in CN107406417?
They encompass a specific heterocyclic scaffold with certain substituents, aiming for broad coverage within this chemical space, but may still face challenges if structurally similar compounds differ notably in core features.
Q2: Does this patent cover only pharmaceutical uses or also chemical synthesis processes?
It includes both, with process claims detailing synthesis routes, providing additional protection of manufacturing methods.
Q3: What diseases does the patent target for therapeutic use?
Mainly cancers and inflammatory disorders, emphasizing treatment efficacy in these areas.
Q4: How does the patent landscape in China influence the value of CN107406417?
China's increasing patent filings in heterocyclic compounds and supportive regulatory policies enhance the patent’s competitive significance, especially domestically.
Q5: What patent strategies should a company consider if developing similar compounds?
Careful structural analysis against claim language, considering filing for related patents or design-around strategies, and proactively monitoring for potential infringement risks.
References
- China National Patent Office (2022). Trend report on pharmaceutical patents.
- CDE Guidelines (2022). Regulatory pathways for innovative drugs in China.
- WIPO Patent Database (2022). Patent landscape of heterocyclic compounds.
- Qilu Pharmaceutical Co., Ltd. (2018). Patent CN107406417 official publication.
- Industry Reports (2021). Pharmaceutical patent filings in China.
For further strategic guidance, stakeholders should regularly consult patent databases, monitor competitors’ filings, and collaborate with patent attorneys specialized in Chinese pharmaceutical patents.
